First-in-human phase I trial of the combination of two adenoviral vectors expressing HSV1-TK and FLT3L for the treatment of newly diagnosed resectable malignant glioma: Initial results from the therapeutic reprogramming of the brain immune system.

This article has no abstract
Epistemonikos ID: ef68fcc441689584a9e2cf33cdfba0ee1abe0ca0
First added on: Feb 11, 2025